Welcome to our dedicated page for Radiopharm Theranostics news (Ticker: RADX), a resource for investors and traders seeking the latest updates and insights on Radiopharm Theranostics stock.
Radiopharm Theranostics Ltd (RADX) is an Australian clinical-stage biopharmaceutical company pioneering targeted radiopharmaceuticals for cancer diagnosis and therapy. This page provides investors and researchers with essential updates on RADX's oncology innovations, including clinical trial progress, strategic collaborations, and regulatory milestones.
Access real-time news about RADX's pipeline developments, including novel agents like 177Lu-RAD202 for HER2-positive cancers and RAD 101 for brain metastasis imaging. Stay informed on partnerships accelerating radiopharmaceutical research and ASX/Nasdaq-listed financial updates.
Key content includes trial phase results, FDA/EMA regulatory filings, licensing agreements, and scientific presentations. All updates are vetted for accuracy and relevance to RADX's mission of advancing precision oncology through theranostics.
Bookmark this page for streamlined access to RADX's latest advancements in radiopharmaceutical science. Check regularly for authoritative updates on clinical developments directly impacting oncology care innovation.
Radiopharm Theranostics (ASX:RAD) presented new data at EMIM 2025 demonstrating positive results for their RAD202 program targeting HER2-positive tumors. The imaging data showed that 68Ga-RAD202 specifically binds to HER2 in xenografts with high tumor-to-background ratio, while the removal of His-tag improved tumor-to-organ ratio for PET imaging.
Treatment with 177Lu-RAD202 demonstrated significant results, including tumor volume reduction and extended survival benefits. Notably, fractionated dosing proved more effective than single-dose therapy. The therapy was well-tolerated in preclinical studies.
These findings support an ongoing First-In-Human Phase I therapeutic trial of 177Lu-RAD202 in HER2-positive solid tumors, currently recruiting in Australia. The trial aims to evaluate safety and preliminary activity in patients with advanced HER2-positive solid tumors who have progressed on standard care or cannot tolerate current treatments.
Radiopharm Theranostics (NASDAQ: RADX) has announced successful clinical trial results for RAD 101 (18F-Pivalate) in detecting brain metastases. The study, published in the European Journal of Nuclear Medicine and Molecular Imaging, demonstrated effective detection using a novel hybrid imaging approach combining PET and Multiparametric MRI.
The trial included 22 patients (12 treatment-naïve and 10 previously treated with brain radiation), showing successful detection of brain metastases regardless of tumor origin, with high tumor-to-background ratio. RAD 101, targeting fatty acid metabolism in solid tumors, has shown promising results in detecting cerebral metastases.
The company is currently conducting a Phase 2b clinical trial in the United States to evaluate RAD 101's diagnostic performance in patients with suspected recurrent brain metastases from solid tumors. This advancement could potentially improve upon current standard-of-care Contrast Enhanced MRI, which has sensitivity in distinguishing disease progression from radiotherapy effects.
Radiopharm Theranostics (NASDAQ:RADX) has secured a US$5.0 million (A$8.0 million) private placement from Lantheus Holdings Inc., strengthening their strategic partnership. The placement consists of 133 million shares at A$0.060 per share, representing a significant 150% premium to the last traded price of A$0.024.
Following this investment, Lantheus becomes Radiopharm's largest shareholder, increasing its stake to 12.16% of the company. The placement replaces 6-month options issued in August 2024, with settlement expected within 7 days. The funds will be directed towards developing Radiopharm's clinical pipeline in oncology radiopharmaceuticals.
Radiopharm Theranostics (ASX:RAD) has entered into a strategic co-development partnership with Lantheus to advance clinical development of radiopharmaceuticals in Australia. The collaboration will initially focus on a basket clinical trial targeting multiple solid tumors. Under the agreement, Lantheus will cover all clinical development costs, and Radiopharm will receive up to USD 2 million in milestone payments for achieving key objectives in the first imaging trial, including ethics committee approval, first patient dosing, and completion of patient enrollment. Radiopharm will lead the clinical development efforts in Australia, leveraging its infrastructure and experience in the field.
Radiopharm Theranostics (ASX:RAD) has received ethics approval in Australia to initiate a Phase 1 First-In-Human therapeutic trial of 177Lu-RAD202 for treating HER2-expressing solid tumors. The open-label trial, named 'HEAT' (HER2 Antibody Therapy with Lutetium-177), will evaluate safety and preliminary clinical activity in patients with HER2-expressing advanced cancers.
The multicenter study follows previous successful data showing safety and biodistribution of 99mTc-labeled RAD 202 in humans. Preclinical findings with 177Lu-labeled RAD 202 demonstrated tumor growth inhibition and significantly prolonged survival time in HER2-positive xenografts. The treatment targets HER2, which is overexpressed in breast cancer and other solid tumors.
Radiopharm Theranostics announces the listing of its American Depositary Shares (ADSs) on the Nasdaq Capital Market under the ticker symbol RADX, effective November 27, 2024. Each ADS represents 300 ordinary shares, complementing the company's primary ASX listing. The Nasdaq listing was achieved without an associated capital raise, with Deutsche Bank Trust Company Americas appointed as depositary. Currently, 21% of Radiopharm's shareholders are US-based. The company expects initial trading volume may be as existing shareholders convert ordinary shares to ADSs.
FAQ
What is the current stock price of Radiopharm Theranostics (RADX)?
What is the market cap of Radiopharm Theranostics (RADX)?
